Fluid overload in hemodialysis patients: A cross-sectional study to determine its association with cardiac biomarkers and nutritional status

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Antlanger, Marlies ^a   Hecking, Manfred ^a   Haidinger, Michael ^a   Werzowa, Johannes ^a   Kovarik, Johannes J ^a   Paul, Gernot ^a   Eigner, Manfred ^b   Bonderman, Diana ^a   Hörl, Walter H ^a   Säemann, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Bioimpedance; Cardiovascular; Fuid overload; Hemodialysis; Inflammation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; D DIMER; SERUM ALBUMIN; TROPONIN T;

ALBUMIN BLOOD LEVEL; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR RISK; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EXTRACELLULAR FLUID; HEART MUSCLE ISCHEMIA; HEMODIALYSIS PATIENT; HUMAN; HYPERVOLEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; NUTRITIONAL STATUS; WEIGHT GAIN;

AUSTRIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NUTRITIONAL STATUS; OBESITY; PEPTIDE FRAGMENTS; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; STATISTICS AS TOPIC; SURVIVAL RATE; WATER-ELECTROLYTE IMBALANCE;

EID: 84888626549     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-266     Document Type: Article

References (44)

1. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van Wyck D, Bunnapradist S, Horwich TB, Fonarow GC, Circulation 2009 119 5 671 679 10.1161/CIRCULATIONAHA.108.807362 19171851
2. The mortality risk of overhydration in haemodialysis patients. Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-Masalska T, Marcelli D, Nephrol Dial Transplant 2009 24 5 1574 1579 10.1093/ndt/gfn707 19131355
3. Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Jacobs LH, van de Kerkhof JJ, Mingels AM, Passos VL, Kleijnen VW, Mazairac AH, van der Sande FM, Wodzig WK, Konings CJ, Leunissen KM, et al. Nephrol Dial Transplant 2010 25 1 243 248 10.1093/ndt/gfp417 19692417
4. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. David S, Kümpers P, Seidler V, Biertz F, Haller H, Fliser D, Nephrol Dial Transplant 2008 23 4 1370 1377 18089624 (Pubitemid 351767474)
5. Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients. Chazot C, Vo-Van C, Zaoui E, Vanel T, Hurot JM, Lorriaux C, Mayor B, Deleaval P, Jean G, Nephrol Dial Transplant 2011 26 8 2630 2634 10.1093/ndt/gfq804 21273234
6. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. Hickman PE, McGill DA, Talaulikar G, Hiremagalur B, Bromley J, Rahman A, Koerbin G, Southcott E, Potter JM, Intern Med J 2009 39 12 812 818 10.1111/j.1445-5994.2009.01846.x 20233242
7. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE, Clin Chim Acta 2010 411 13-14 936 939 20298685
8. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Kirmizis D, Tsiandoulas A, Pangalou M, Koutoupa E, Rozi P, Protopappa M, Barboutis K, Med Sci Monit 2006 12 2 R55 CR62 16449948
9. Is N-terminal probrain-type natriuretic peptide a clinically useful biomarker of volume overload in peritoneal dialysis patients? Papakrivopoulou E, Lillywhite S, Davenport A, Nephrol Dial Transplant 2012 27 1 396 401 10.1093/ndt/gfr338 21765049
10. N-terminal proBNP-marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients? Booth J, Pinney J, Davenport A, Clin J Am Soc Nephrol 2010 5 6 1036 1040 10.2215/CJN.09001209 20507952
11. B-type natriuretic peptide and interdialytic fluid retention are independent and incremental predictors of mortality in hemodialysis patients. Westenbrink BD, Hovinga TK, Kloppenburg WD, Veeger NJ, Janssen WM, Clin Nephrol 2011 76 5 373 379 22000557
12. Upregulation of surrogate markers of inflammation and thrombogenesis in patients with ESRD: pathophysiologic and therapeutic implications. Nelson K, Thethi I, Cunanan J, Hoppensteadt D, Bajwa R, Fareed J, Bansal V, Clin Appl Thromb Hemost 2011 17 3 302 304 10.1177/1076029610387127 21159713
13. Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays. Jacobs LH, van de Kerkhof J, Mingels AM, Kleijnen VW, van der Sande FM, Wodzig WK, Kooman JP, Van Dieijen-Visser MP, Ann Clin Biochem 2009 46 Pt 4 283 290 19454537
14. Cardiac biomarkers and survival in haemodialysis patients. Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA, Giannitsis E, Zeier M, Eur J Clin Invest 2007 37 5 350 356 10.1111/j.1365-2362.2007.01785.x 17461980 (Pubitemid 46653136)
15. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, et al. Clin J Am Soc Nephrol 2011 6 1 133 141 10.2215/CJN.04610510 20876680
16. Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Gonçalves S, Pecoits-Filho R, Perreto S, Barberato SH, Stinghen AE, Lima EG, Fuerbringer R, Sauthier SM, Riella MC, Nephrol Dial Transplant 2006 21 10 2788 2794 10.1093/ndt/gfl273 16861246 (Pubitemid 44542232)
17. Hypervolemia is associated with increased mortality among hemodialysis patients. Agarwal R, Hypertension 2010 56 3 512 517 10.1161/HYPERTENSIONAHA.110. 154815 20625076
18. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Paniagua R, Ventura MD, Avila-Díaz M, Hinojosa-Heredia H, Méndez-Durán A, Cueto-Manzano A, Cisneros A, Ramos A, Madonia-Juseino C, Belio-Caro F, et al. Nephrol Dial Transplant 2010 25 2 551 557 10.1093/ndt/gfp395 19679559
19. Significance of interdialytic weight gain versus chronic volume overload: consensus opinion. Hecking M, Karaboyas A, Antlanger M, Saran R, Wizemann V, Chazot C, Rayner H, Hörl WH, Pisoni RL, Robinson BM, et al. Am J Nephrol 2013 38 1 78 90 10.1159/000353104 23838386
20. Living on chronic hemodialysis between dryness and fluid overload. Franz M, Pohanka E, Tribl B, Woloszczuk W, Hörl WH, Kidney Int Suppl 1997 59 39 S42 9185103
21. Dry weight: sine qua non of adequate dialysis. Wystrychowski G, Levin NW, Adv Chronic Kidney Dis 2007 14 3 10 e16 10.1053/j.ackd.2007.03.003 17603970 (Pubitemid 46977284)
22. Evaluation of clinical dry weight assessment in haemodialysis patients using bioimpedance spectroscopy: a cross-sectional study. Passauer J, Petrov H, Schleser A, Leicht J, Pucalka K, Nephrol Dial Transplant 2010 25 2 545 551 10.1093/ndt/gfp517 19808949
23. Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Wabel P, Chamney P, Moissl U, Jirka T, Blood Purif 2009 27 1 75 80 10.1159/000167013 19169022
24. Body fluid volume determination via body composition spectroscopy in health and disease. Moissl UM, Wabel P, Chamney PW, Bosaeus I, Levin NW, Bosy-Westphal A, Korth O, Müller MJ, Ellegård L, Malmros V, et al. Physiol Meas 2006 27 9 921 933 10.1088/0967-3334/27/9/012 16868355 (Pubitemid 44131442)
25. Current state of bioimpedance technologies in dialysis. Kotanko P, Levin NW, Zhu F, Nephrol Dial Transplant 2008 23 3 808 812 18182405 (Pubitemid 351767595)
26. Guided optimization of fluid status in haemodialysis patients. Machek P, Jirka T, Moissl U, Chamney P, Wabel P, Nephrol Dial Transplant 2010 25 2 538 544 10.1093/ndt/gfp487 19793930
27. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, Kurokawa K, Piera L, Saito A, Fukuhara S, et al. Kidney Int 2003 64 1 254 262 10.1046/j.1523-1755.2003.00064.x 12787417 (Pubitemid 36714179)
28. Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial. Hecking M, Antlanger M, Winnicki W, Reiter T, Werzowa J, Haidinger M, Weichhart T, Polaschegg HD, Josten P, Exner I, et al. Trials 2012 13 79 10.1186/1745-6215-13- 79 22682149
29. Improved intradialytic stability during haemodialysis with blood volume-controlled ultrafiltration. Gabrielli D, Krystal B, Katzarski K, Youssef M, Hachache T, Lopot F, Lasseur C, Gunne T, Draganov B, Wojke R, et al. J Nephrol 2009 22 2 232 240 19384841
30. Intra-dialytic hypotension and blood volume and blood temperature monitoring. Damasiewicz MJ, Polkinghorne KR, Nephrology 2011 16 1 13 18 10.1111/j.1440-1797.2010.01362.x 21175972
31. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Charlson ME, Pompei P, Ales KL, MacKenzie CR, J Chronic Dis 1987 40 5 373 383 10.1016/0021-9681(87)90171-8 3558716 (Pubitemid 17055592)
32. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, Greenland S, Am J Kidney Dis 2005 46 3 489 500 10.1053/j.ajkd.2005.05.020 16129211 (Pubitemid 41208185)
33. Survival advantages of obesity in dialysis patients. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB, Am J Clin Nutr 2005 81 3 543 554 15755821
34. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, Pfeffer MA, Yusuf S, Swedberg K, Michelson EL, et al. Circulation 2007 116 6 627 636 10.1161/CIRCULATIONAHA.106.679779 17638930 (Pubitemid 47356347)
35. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. O'Connor CM, Whellan DJ, Wojdyla D, Leifer E, Clare RM, Ellis SJ, Fine LJ, Fleg JL, Zannad F, Keteyian SJ, et al. Circ Heart Fail 2012 5 1 63 71 10.1161/CIRCHEARTFAILURE.111.963462 22114101
36. Hydration status assessment by multi-frequency bioimpedance in patients with advanced chronic kidney disease. Caravaca F, Martínez Del Viejo C, Villa J, Martínez Gallardo R, Ferreira F, Nefrologia 2011 31 5 537 544 21959720
37. Dialysis patients' fluid overload, antihypertensive medications, and obesity. Tapolyai M, Faludi M, Réti V, Lengvárszky Z, Szarvas T, Berta K, ASAIO J 2011 57 6 511 515 10.1097/MAT.0b013e3182377216 21989422
38. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD, Hypertension 2005 45 4 811 817 10.1161/01.HYP.0000154895.18269.67 15699452 (Pubitemid 40418386)
39. The Nutritional and Inflammatory Evaluation in Dialysis patients (NIED) study: overview of the NIED study and the role of dietitians. Colman S, Bross R, Benner D, Chow J, Braglia A, Arzaghi J, Dennis J, Martinez L, Baldo DB, Agarwal V, et al. J Ren Nutr 2005 15 2 231 243 10.1053/j.jrn.2005.01.003 15827897
40. Optimal fluid control can normalize cardiovascular risk markers and limit left ventricular hypertrophy in thrice weekly dialysis patients. Velasco N, Chamney P, Wabel P, Moissl U, Imtiaz T, Spalding E, McGregor M, Innes A, MacKay I, Patel R, et al. Hemodial Int 2012 16 4 465 472 10.1111/j.1542-4758.2012. 00689.x 22515643
41. Towards improved cardiovascular management: the necessity of combining blood pressure and fluid overload. Wabel P, Moissl U, Chamney P, Jirka T, Machek P, Ponce P, Taborsky P, Tetta C, Velasco N, Vlasak J, et al. Nephrol Dial Transplant 2008 23 9 2965 2971 10.1093/ndt/gfn228 18458032
42. Interdialytic blood pressure obtained by ambulatory blood pressure measurement and left ventricular structure in hypertensive hemodialysis patients. Mominadam S, Ozkahya M, Kayikcioglu M, Toz H, Asci G, Duman S, Ergin P, Kirbiyik S, Ok E, Basci A, Hemodial Int 2008 12 3 322 327 10.1111/j.1542-4758.2008.00275.x 18638087
43. Cross-talk between inflammation,coagulation/fibrinolysis and vascular access in hemodialysis patients. Costa E, Rocha S, Rocha-Pereira P, Castro E, Reis F, Teixeira F, Miranda V, Do Sameiro Faria M, Loureiro A, Quintanilha A, et al. J Vasc Access 2008 9 4 248 253 19085894
44. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, Levey AS, Lewis EF, McMurray JJ, Parving HH, et al. Am J Kidney Dis 2011 58 5 717 728 10.1053/j.ajkd.2011.05.020 21820220